Literature DB >> 22974853

The use of neoplastic donors to increase the donor pool.

P Fiaschetti1, R Pretagostini, D Stabile, D Peritore, A Oliveti, F Gabbrielli, S Cenci, A Ricci, F Vespasiano, W F Grigioni.   

Abstract

The aim of the study was to evaluate the experience of the Centre-Sud Transplant Organization (OCST) area using cadaveric donor with neoplastic diseases to evaluate the possibility of transmission to recipients. From January 1, 2003, to December 31, 2010, the neoplastic risk has been reported to be 5.4% (377/4654 referred donors). In 2003, the number of donors with a tumor and their mean age were respectively: 60 (10.3%) and 59.6 ± 19.9; 2004: 33 (5.2%) and 61.4 ± 15.9; 2005: 32 (6%) and 62.8 ± 15.5; 2006: 46 (7%) and 60.7 ± 19.1; 2007: 51 (7%) and 58.9 ± 16; in 2008: 58 (7%) and 59.7 ± 19.6; 2009: 47 (7%) and 57 ± 26; 2010: 49 (7%) and 64 ± 16. The organ most affected by tumor has been the central nervous system (18%). The tumor was diagnosed before in 325 (86%) cases, versus during organ retrieval in 48 (12.7%) donor operations but before, which four cases (1%) occured after transplantation. According to the histological types and grades, 28 evaluated donors (8.2%) were suitable for transplantation. The histological types were: thyroid carcinoma (n = 3); prostate carcinoma (n = 8), renal clear cell carcinoma (n = 7), oncocytoma (n = 1), meningiomas (n = 2), dermofibrosarcoma (n = 1); verrucous carcinoma of the vulva (n = 1), colon adenocarcinoma (n = 1), grade II astrocytoma (n = 1), adrenal gland tumor (n = 1), gastric GIST (n = 1), oligodendroglioma (n = 1). Forty-five organs were retrieved (22 livers, 19 kidneys, 3 hearts, and 1 pancreas) and transplanted into 44 recipients with 1 liver-kidney combined transplantation. Four recipients died due to causes not related to the tumor. No donor-transmitted tumor was detected among the recipients. Donation is absolutely not indicated in cases of tumors with high metastatic potential and high grades. Performing an accurate evaluation of the donor, taking into account the histological grade, currently can allow, organ retrieval and transplantation with an acceptable risk.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22974853     DOI: 10.1016/j.transproceed.2012.06.030

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

Review 1.  Strategies to optimize the use of marginal donors in liver transplantation.

Authors:  Daniele Pezzati; Davide Ghinolfi; Paolo De Simone; Emanuele Balzano; Franco Filipponi
Journal:  World J Hepatol       Date:  2015-11-18

2.  [Urological follow-up and development of cancer after renal transplantation].

Authors:  M Giessing
Journal:  Urologe A       Date:  2015-10       Impact factor: 0.639

Review 3.  Transplantation of kidneys with tumors.

Authors:  Giovanni M Frascà; Antonia D'Errico; Deborah Malvi; Camillo Porta; Laura Cosmai; Matteo Santoni; Silvio Sandrini; Chiara Salviani; Maurizio Gallieni; Emilio Balestra
Journal:  J Nephrol       Date:  2015-11-20       Impact factor: 3.902

4.  Donor-Transmitted Cancer in Orthotopic Solid Organ Transplant Recipients: A Systematic Review.

Authors:  George H B Greenhall; Maria Ibrahim; Utkarsh Dutta; Carolyn Doree; Susan J Brunskill; Rachel J Johnson; Laurie A Tomlinson; Chris J Callaghan; Christopher J E Watson
Journal:  Transpl Int       Date:  2022-02-04       Impact factor: 3.842

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.